SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

Viruses. 2021 Jun 23;13(7):1211. doi: 10.3390/v13071211.

Abstract

We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.

Keywords: COVID-19; LyCoV016; REGN10987; SARS-CoV-2; convalescent plasma; etesevimab; imdevimab; immune escape; mutations; neutralizing antibody.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / blood*
  • COVID-19 / therapy
  • COVID-19 Serotherapy
  • Humans
  • Immunization, Passive / standards
  • In Vitro Techniques
  • Neutralization Tests
  • Plasma / immunology*
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / immunology
  • Viral Vaccines / immunology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines
  • imdevimab
  • etesevimab